ESR1 and breast carcinoma: Another encouraging prospect for the future reduction of these harms in older women are the recent results of PRIME II trial, which showed that omission of adjuvant radiotherapy did not affect survival in women 65 years or older with T1-T2, node-negative, estrogen receptor positive breast cancer [49].